⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PLX News
Protalix BioTherapeutics, Inc. Common Stock
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼
globenewswire.com
PLX
Form 8-K
sec.gov
PLX
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
globenewswire.com
PLX
Ellomay Capital Announces Changes in its Principal Shareholders and Board Composition
globenewswire.com
PLX
ELLO
Germany Gift Card Business and Investment Report 2026-2030: Universal Voucher Innovation, Third-Party Infrastructure Expansion and Employer-Funded Rewards Intensify Competitive Dynamics
globenewswire.com
PLX
France Prepaid Card and Digital Wallet Intelligence Report 2026: Market to Expand by 6.3% to Reach $38.44 Billion this Year - Future Growth Dynamics to 2030
globenewswire.com
PLX
Brazil Prepaid Card and Digital Wallet Intelligence Report 2026: Edenred, Pluxee, Alelo and VR Dominate Programs While Central Bank Priorities and Pix Integration Shape the Next Phase of Competition
globenewswire.com
EDN
PLX
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
globenewswire.com
PLX
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
globenewswire.com
PLX
Fishing Net Recycling & Reuse Market Forecast 2025-2030 | Fishing Net Recycling is Transforming Marine Conservation and The Circular Economy
globenewswire.com
PLX